Study of Adzynma in cTTP patients
Part of Blood & lymphatic clinical trials.
This study observes children and adults with cTTP who have already used Adzynma. It aims to gather more information about the treatment's real-world effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with congenital thrombotic thrombocytopenic purpura (cTTP).
- You must have taken Adzynma (the approved treatment) for cTTP before, with at least one dose recorded in your medical records.
- You must not have a history of an ADAMTS13 inhibitor (antibodies that block the medication).
- You must not be taking any other investigational drug or be enrolled in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study reviews medical records of people with a rare blood clotting disorder called cTTP who received a treatment called rADAMTS13 through an early access program. The goal is to learn more about how the treatment works in real life.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This trial tests whether taking aspirin daily can help prevent the blood-clotting episodes (called TTP) caused by a severe lack of a specific protein in your blood. If you have a history of TTP or a genetic form that increases your risk, this study may help reduce those dangerous episodes.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
Hear when a new Thrombotic Thrombocytopenic Purpura (TTP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.